Matches in SemOpenAlex for { <https://semopenalex.org/work/W2225170349> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2225170349 startingPage "26" @default.
- W2225170349 abstract "Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF) generates potent, specific, and long-lasting anti-tumor immunity in murine models through improved tumor antigen presentation by mature CD11b+ dendritic cells and macrophages. The coordinated activities of CD4+ and CD8+ T cells, CD1d-restricted invariant NKT cells, and antibodies accomplish protective immunity. Two Phase I clinical trials evaluating this immunization scheme in patients with disseminated melanoma revealed the consistent elicitation in distant metastases of dense T- and B-cell infiltrates that effectuated substantial tumor necrosis and fibrosis. In a pilot study of previously vaccinated patients, the subsequent administration of a humanized blocking antibody against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) stimulated additional tumor destruction with lymphocyte and granulocyte infiltrates, albeit with the development of T-cell reactivity to normal melanocytes. Studies to date established that patients responding to vaccination developed high titer IgG antibodies that were reactive with cell surface and intracellular melanoma determinants as demonstrated by immunoblotting and flow cytometry. Lymphocytes harvested from infiltrated metastases displayed potent cytotoxicity and broad cytokine production towards autologous melanoma cells. Through a combination of antibody-based expression cloning and T-cell epitope characterization, the ATP6S1 subunit of the vacuolar-ATPase complex, the putative opioid growth factor receptor OGFr, and the melanoma inhibitor of apoptosis protein (ML-IAP) were identified as target antigens for antibodies or T cells in some long-term responding patients. Unexpectedly, humoral reactions to ATP6S1 and OGFr were associated with tumor destruction in patients with diverse cancers. Moreover, the delineation of ML-IAP as a target revealed that antigen-loss variants could mediate immune evasion within the context of whole tumor cell vaccines. Additional detailed analysis of blood and tumor samples from responding and resistant patients in these clinical trials should help elucidate the mechanisms and targets of immune-mediated tumor destruction. This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research." @default.
- W2225170349 created "2016-06-24" @default.
- W2225170349 creator A5028608171 @default.
- W2225170349 date "2005-01-01" @default.
- W2225170349 modified "2023-09-23" @default.
- W2225170349 title "GM-CSF based cancer vaccines" @default.
- W2225170349 hasPublicationYear "2005" @default.
- W2225170349 type Work @default.
- W2225170349 sameAs 2225170349 @default.
- W2225170349 citedByCount "1" @default.
- W2225170349 crossrefType "journal-article" @default.
- W2225170349 hasAuthorship W2225170349A5028608171 @default.
- W2225170349 hasConcept C147483822 @default.
- W2225170349 hasConcept C154317977 @default.
- W2225170349 hasConcept C159654299 @default.
- W2225170349 hasConcept C167672396 @default.
- W2225170349 hasConcept C202751555 @default.
- W2225170349 hasConcept C203014093 @default.
- W2225170349 hasConcept C2776662205 @default.
- W2225170349 hasConcept C2777701055 @default.
- W2225170349 hasConcept C2780674031 @default.
- W2225170349 hasConcept C502942594 @default.
- W2225170349 hasConcept C55493867 @default.
- W2225170349 hasConcept C86803240 @default.
- W2225170349 hasConcept C8891405 @default.
- W2225170349 hasConceptScore W2225170349C147483822 @default.
- W2225170349 hasConceptScore W2225170349C154317977 @default.
- W2225170349 hasConceptScore W2225170349C159654299 @default.
- W2225170349 hasConceptScore W2225170349C167672396 @default.
- W2225170349 hasConceptScore W2225170349C202751555 @default.
- W2225170349 hasConceptScore W2225170349C203014093 @default.
- W2225170349 hasConceptScore W2225170349C2776662205 @default.
- W2225170349 hasConceptScore W2225170349C2777701055 @default.
- W2225170349 hasConceptScore W2225170349C2780674031 @default.
- W2225170349 hasConceptScore W2225170349C502942594 @default.
- W2225170349 hasConceptScore W2225170349C55493867 @default.
- W2225170349 hasConceptScore W2225170349C86803240 @default.
- W2225170349 hasConceptScore W2225170349C8891405 @default.
- W2225170349 hasLocation W22251703491 @default.
- W2225170349 hasOpenAccess W2225170349 @default.
- W2225170349 hasPrimaryLocation W22251703491 @default.
- W2225170349 hasRelatedWork W1888836615 @default.
- W2225170349 hasRelatedWork W1994194611 @default.
- W2225170349 hasRelatedWork W2011653164 @default.
- W2225170349 hasRelatedWork W2042170451 @default.
- W2225170349 hasRelatedWork W2065207101 @default.
- W2225170349 hasRelatedWork W2089456457 @default.
- W2225170349 hasRelatedWork W2102913940 @default.
- W2225170349 hasRelatedWork W2105017308 @default.
- W2225170349 hasRelatedWork W2106775454 @default.
- W2225170349 hasRelatedWork W2116286338 @default.
- W2225170349 hasRelatedWork W2121080857 @default.
- W2225170349 hasRelatedWork W2148235191 @default.
- W2225170349 hasRelatedWork W2164991707 @default.
- W2225170349 hasRelatedWork W2264619705 @default.
- W2225170349 hasRelatedWork W2395936367 @default.
- W2225170349 hasRelatedWork W2607137647 @default.
- W2225170349 hasRelatedWork W280395377 @default.
- W2225170349 hasRelatedWork W2920087977 @default.
- W2225170349 hasRelatedWork W3202718025 @default.
- W2225170349 hasRelatedWork W575671756 @default.
- W2225170349 hasVolume "5" @default.
- W2225170349 isParatext "false" @default.
- W2225170349 isRetracted "false" @default.
- W2225170349 magId "2225170349" @default.
- W2225170349 workType "article" @default.